From:
 Elliott, Robin

 To:
 DRissi@Imhosp.org

 Cc:
 wmlairmore@optonline.net

Subject: Request for Additional Information for Renewal of NRC License No. 06-09261-01

Date: Thursday, April 17, 2014 4:43:00 PM

Docket No. 03001275 License No. 06-09261-01 Control No. 582991

Daniel Rissi, M.D.

VP and Chief Medical Officer
Lawrence & Memorial Hospital
365 Montauk Avenue

New London, CT 08320-4769

SUBJECT: LAWRENCE & MEMORIAL HOSPITAL, REQUEST FOR ADDITIONAL INFORMATION

CONCERNING APPLICATION FOR RENEWAL OF LICENSE, CONTROL NO. 582991

Dear Dr. Rissi:

This is in reference to your application dated January 17, 2014 requesting to amend Nuclear Regulatory Commission License No. 06-09261-01. In order to continue our review, we need the following additional information:

- 1. In order to facilitate future communications please provide your business phone number and facsimile number. In addition, please provide a business email address for your Radiation Safety Officer John Sorrentino, M.D., if he uses one.
- 2. Provide the manufacturer and model number for any sealed sources (other than your 35.500 sources) that do not meet the criteria in 10 CFR 35.65 (e.g. greater than 30 millicuries).
- 3. For your 35.500 sources, please provide the current manufacturers, activity per source and number of sources possessed.
- 4. Please confirm that you no longer wish to list John Sutphen, M.D. and Patrick Lahr, M.D. as Authorized Users on your license.
- 5. Your current license lists the following users with authorization for 35.500: Charles W. Andrias, M.D., Leonard A. Copertino, M.D., and Sheldon Robbins, M.D. Please confirm whether or not you wish to discontinue this authorization for these individuals.
- 6. In your letter dated April 9, 2013 you requested to move your stress lab. There is no information in the docket file indicating that you have decommissioned the old room. Please indicate when material was last used in this location and if/when it was released for unrestricted use. Please submit a closeout survey of the facility.
- 7. Amendment No. 89 added a stress lab on the fifth floor of the hospital. It was not included in the renewal application. If you wish to continue to use this location, please submit the facility diagram indicating what is located in the areas adjacent to, above and below the stress lab. Confirm that no material will be stored in this location and indicate whether the room is restricted or unrestricted as defined in 10 CFR 20.1003.

- 8. With regard to the facility diagrams submitted:
 - a. Please describe what is located in the areas adjacent to, above and below the areas of use, preparation, and storage.
 - b. Describe the security measures in place for all locations where licensed material is stored; i.e. hot labs, trash holding area, etc. (365 Montauck Avenue locations only).
 - c. Please provide a description of shielding, if applicable for waste stored in the second floor "trash holding area," and confirm that public dose limits will be met in all surrounding areas.
- 9. Please re-submit the detailed PET facility shielding design and program information as described in your November 18, 2011 letter. In addition, make the following commitments as agreed upon when you added PET to your license:
 - a. Describe the quality assurance testing program used for the MEDRAD INTEGO infusion system as described in your February 6, 2012 letter.
 - b. Describe the shielding of the MEDRAD INTEGO infusion system as communicated in your letter dated February 6, 2012.
 - c. Please commit that for bulk F-18 dosage material, you will not remove the F-18 dosage vial at any time from the INTEGO VIAL SHIELD provided by the radiopharmacy as previously communicated in your February 22, 2012 letter.

Current NRC regulations and guidance are included on the NRC's website at www.nrc.gov; select Nuclear Materials; Med, Ind, & Academic Uses; then Licensee Toolkits, see our toolkit index page. You may also obtain these documents by contacting the Government Printing Office (GPO) toll-free at 1-866-512-1800. The GPO is open from 8:00 a.m. to 5:30 p.m. EST, Monday through Friday (except Federal holidays).

We will continue our review upon receipt of this information. Please reply to my attention by letter or fax, (610) 337-5269, at the Region I Office and refer to Mail Control No. 582991. If you have any technical questions regarding this deficiency letter, please call me at (610) 337-5076.

If we do not receive a reply from you within 30 calendar days from the date of this email, we will assume that you do not wish to pursue your application.

Sincerely,

Health Physicist

Robin Q. Elliott

U. S. Nuclear Regulatory Commission Region I, Division of Nuclear Materials Safety 2100 Renaissance Blvd

King of Prussia, PA 19406-2713

(610) 337-5076 voice

(610) 337-5269 fax

Robin.Elliott@nrc.gov